NCI-H929/Cre cells are derived from the the human B lymphocyte NCI-H929 cell line by stably integration of a constitutive Cre recombinase stably expression construct. NCI-H929 cells stably express B cell maturation antigen (BCMA)-a novel treatment target for multiple myeloma (MM), and have been widely used in cancer research and drug development. NCI-H929/Cre cells stably express a nuclear localized Cre recombinase.